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OBJECTIVE To identify risk factors for systemic exposure to vancomycin (VAN) following administra-
tion of oral vancomycin (POV) for the treatment of Clostridium difficile infection (CDI).
DESIGN Prospective, observational, single-center case series.
SETTING Academic medical center.
PATIENTS Hospitalized patients with suspected or confirmed CDI who received POV for at least 5 days.
INTERVENTION Random VAN serum levels were obtained on days 5, 10, and weekly thereafter in
patients treated for ≥ 5 days with POV without concomitant intravenous VAN.
MEASUREMENTS AND RESULTS Of 117 random VAN serum levels from 85 patients, 58 patients (68.2%) had
one or more detectable (≥ 0.05 lg/ml) levels and 15 (17.6%) of 85 patients had one or more levels
> 2.5 lg/ml. Risk factors for detectable VAN exposure following administration of POV included POV
dosages > 500 mg/day (odds ratio [OR] 35.83, 95% confidence interval [CI] 7.56–169.8), the presence
of severe CDI (OR 4.11, 95% CI 2.76–10.83, p=0.028), intensive care unit (ICU) admission (OR 3.80,
95% CI 1.02–14.21, p=0.032), and the administration of POV ≥ 10 days (OR 6.71, 95% CI 1.81–
24.83, p=0.0025). Risk factors for exposure to serum VAN concentrations > 2.5 lg/ml included the
presence of gastrointestinal (GI) pathology (OR 5.22, 95% CI 3.45–18.3, p=0.031), ICU admission
(OR 3.21, 95% CI 1.40–10.28, p=0.022), the use of VAN retention enemas (OR 4.73, 95% CI 2.42–
20.39, p=0.036), and having a creatinine clearance ≤ 50 ml/minute or undergoing hemodialysis or
continuous renal replacement therapy (OR 4.03, 95% CI 1.26–12.84, p=0.039).
CONCLUSIONS Serum VAN levels were detected in 58 (68.2%) of 85 patients receiving POV for CDI.
Risk factors for systemic exposure to VAN following administration of POV included ICU
admission; VAN dosages > 500 mg/day; administration ≥ 10 days or as retention enemas; and the
presence of severe CDI, renal dysfunction, or inflammatory conditions of the GI tract. Unique to
our study, we identified ICU admission and the concomitant use of VAN retention enemas to be
significant risk factors for systemic exposure to VAN.
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O R I G I N A L R E S E A R C H A R T I C L E S
Current practice guidelines for the manage-
ment of Clostridium difficile infection (CDI) in
adults recommend the use of oral vancomycin
(POV) at a dosage of 125 mg every 6 hours in
the setting of a severe initial episode of CDI
(patients who present with white blood cell
count [WBC] > 15,000 or serum creatinine
[Scr] ≥ 1.5 times the premorbid level).
1 In
patients with an initial episode complicated by
hypotension or shock, ileus, or megacolon, the
dosage of POV should be 500 mg every
6 hours, given in combination with intravenous
(IV) metronidazole 500 mg every 8 hours.1, 2
The use of POV has significantly increased over
the past several years as a result of increased
rates of CDI in many health care institutions
worldwide and the emergence and rapid spread
of a previously rare strain, known synony-
mously as polymerase chain reaction ribotype
027, North American Pulse-field type 1, or
restriction endonuclease analysis type BI.3 At
the University of Michigan Hospitals, use of
POV increased steadily over the years from 0.5
unique POV starts per 1000 patient-days in
2005 to 2.6 in 2008.
Vancomycin (VAN) is a poorly absorbed anti-
microbial agent. Oral administration of VAN to
healthy individuals results in undetectable
plasma and low (< 1 lg/ml) urine concentra-
tions,4–6 and low (≤ 1 lg/ml) serum levels in
anephric subjects without inflammatory bowel
disease.6 However, previously published case
reports and case series (including one from our
institution7) suggested that certain patient popu-
lations may be at greater risk for systemic
absorption of POV.8–14
VAN plasma concentrations as high as 58.7 lg/
ml following administration of POV have been
documented in patients with renal failure,8–13
and in those administered POV at higher dosages
(500 mg every 6 hr)9, 11, 13, 15 or for prolonged
durations (> 10 days) of therapy.11, 13 Patients
with severe pseudomembranous colitis,13, 16 gas-
trointestinal (GI) graft-versus-host disease
(GVHD),7 or other inflammatory conditions of
the GI tract such as Crohn disease or inflamma-
tory bowel disease6, 14, 17 have also experienced
elevated plasma levels of VAN. Given reports of
high serum concentrations in these settings, cur-
rent Infectious Diseases Society of America
(IDSA) practice guidelines for CDI in adults sug-
gest monitoring serum VAN concentrations in
patients with renal failure receiving long courses
of 2 g/day.1
Although high VAN serum levels are concern-
ing for toxicity and accumulation, levels
< 10 lg/ml may also be of concern9, 11, 15, 17, 18
because prolonged exposure to VAN at serum
levels < 10 lg/ml may be associated with the
development of resistant strains of Staphylococ-
cus aureus including VAN-intermediate S. aureus
(VISA) and VAN-resistant S. aureus (VRSA).19–21
Although a number of previous case reports
or case series have proposed potential risk fac-
tors for the absorption of POV, none have statis-
tically analyzed a large group of patients to
determine independent risk factors associated
with VAN exposure in patients with CDI. The
goal of our study was to identify risk factors for
systemic exposure to VAN following administra-
tion of POV for the treatment of CDI.
Materials and Methods
Study Design
All adult and pediatric patients with suspected
or confirmed CDI between February 2010 and
June 2011 who received POV (reconstituted
from IV solution) for at least 5 days were
included in this prospective observational single-
center case series. Patients were excluded from
the study if they were receiving concomitant IV
VAN or had received IV VAN within the previ-
ous 30 days. Given the half-life of VAN in the
setting of hemodialysis (HD) of 7 days, 1 month
was determined to be an adequate washout
period.
Data Collection
A random serum VAN level was obtained after
at least 5 days of therapy. All samples were
obtained as random concentrations irrespective of
the timing of the level to the prior POV dose.
Most of the serum concentrations were obtained
from discarded samples initially obtained for rou-
tine clinical laboratory monitoring. Samples were
stored immediately in the laboratory refrigerator,
centrifuged within 4 hours, and placed into a
freezer (15°C to 20°C) to maintain sample
integrity where they remained until enough sam-
ples were available to run as a batch to analyze
serum concentrations. If patients remained on
POV > 10 days, a serum VAN level was obtained
every 7–10 days thereafter while the patients
remained hospitalized. We prospectively col-
lected data to assess potential risk factors for
120 PHARMACOTHERAPY Volume 35, Number 2, 2015
VAN exposure including POV dosages > 500 mg/
day or administration ≥ 10 days, the presence of
severe CDI based on the Society for Healthcare
Epidemiology of America (SHEA)/IDSA guide-
lines (i.e., findings of WBC > 15,000 or Scr > 1.5
times the premorbid level),1 intensive care unit
(ICU) admission, the presence of GI pathology
(e.g., inflammatory bowel disease, Crohn disease,
or GI GVHD), the use of VAN retention enemas,
and the presence of renal dysfunction (defined as
a creatinine clearance [Clcr] ≤ 50 ml/min, or the
use of HD or continuous renal replacement ther-
apy [CRRT]). The Clcr was calculated using the
Cockcroft and Gault equation.22
The study was conducted in accordance with
the ethical standards and approval of our institu-
tion’s Human Research Protection Program. All
VAN samples were batched for bulk analysis;
thus clinicians caring for patients did not receive
notification of VAN concentrations except in the
two instances in which VAN levels had been
obtained during routine patient care. VAN
serum concentration assays were performed
using the Roche Integra 800 Analyzer that has a
limit of detection (at a 95% confidence level) of
1.39 lg/ml. Patient samples, which were ana-
lyzed in duplicate, displayed a coefficient of var-
iation (CV) of VAN concentrations < 10% at
concentrations of 1.39–20 lg/ml. At concentra-
tions ≥ 0.05 lg/ml but < 1.3, VAN levels were
detectable, but CVs were > 15%. None of the
patients was receiving concomitant therapy with
telavancin, which can cause false-positive VAN
levels when utilizing a particle-enhanced turbidi-
metric inhibition immunoassay.23
Statistical Analysis
The primary and secondary outcomes of inter-
est were identification of risk factors associated
with systemic exposure to VAN following admin-
istration of POV and the incidence of systemic
exposure following the administration of POV
among those treated for confirmed CDI, respec-
tively. Bivariate and multivariate analyses were
performed to determine identifiable risk factors
associated with systemic exposure to VAN. Poten-
tial risk factors assessed included age, gender,
weight in kilograms, renal function (calculated
Clcr or requirement of renal replacement ther-
apy), comorbid disease states (e.g., renal failure,
GVHD, etc.), concomitant medications (specifi-
cally other nephrotoxins), dosage/duration of
POV, and GI pathology (GVHD of the GI tract,
inflammatory bowel disease, or Crohn disease).
Bivariate analysis was completed using t tests
or the Mann-Whitney U test for continuous
variables and the v2 or Fisher exact test for
categorical variables to identify factors associ-
ated with systemic exposure to VAN. Given the
limitations of our VAN assay, and the variabil-
ity of the assay at low (< 1 lg/ml) concentra-
tions, we chose to analyze risk factors for both
detectable levels and levels > 2.5 lg/ml. The
2.5 lg/ml threshold value was selected by the
investigators as clinically relevant, monitorable,
and above the lower limit of detection at most
institutions. Measurement of this level in a
patient not receiving IV VAN would indicate
systemic accumulation and exposure. In addi-
tion, available evidence suggests that VAN lev-
els < 10 lg/ml are associated with the
development of VAN resistance.19–21 However,
analyses after selection of other VAN threshold
concentrations yielded similar results (data not
shown). Crude odds ratios (ORs) and 95% CIs
were calculated for categorical data variables,
and ORs for continuous variables were obtained
using a simple logistic regression. Variables
with p values ≤ 0.20 in the bivariate analysis
or that had a priori clinical significance were
included separately in multivariate modeling
and maintained if their inclusion changed the
OR for the primary risk factor of interest by
≥ 15%.24 A two-tailed test of significance with
a p value ≤ 0.05 was considered statistically
significant. All statistical analyses were per-
formed using SPSS software v.21 (IBM, Las
Vegas, NV) and StatView v.5.0.1 (SAS institute,
Inc., Cary, NC).
Results
A total of 85 patients receiving POV were
included in the analysis (79 adults and 6 chil-
dren). Almost 50% of the patients were male, and
the mean age of all patients was
54.8  21.9 years. However, patients with
detectable (≥ 0.05 lg/ml) levels of POV were sig-
nificantly older than patients with undetectable
levels (61.5 + 20.2 yrs and 40.3 + 19.2 yrs,
respectively, p<0.005). The six children in the
study were 18, 17, 15, 15, 8, and 6 years of age.
Daily POV dosages and the maximum plasma lev-
els measured in the children were 500, 1000,
2000, 2000, 735, and 880 mg, and 1.6 lg/ml,
nondetectable, nondetectable, 1.0 lg/ml, nonde-
tectable, and 0.91 lg/ml, respectively.
POV dosages ranged from 62.25–2000 mg/
day; the median dosage was 500 mg/day. Of
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note, only eight patients (two of whom were chil-
dren, 15 yrs of age) received high (2000 mg/day)
POV dosages. During the analysis period, 117
random VAN levels were obtained from the 85
patients; VAN levels were detectable in 74
(63.2%; Table 1). Fifty-eight patients (68.2%)
had one or more detectable (≥ 0.05 lg/ml) lev-
els, ranging from 0.05 to 9.94 lg/ml, and 15
patients (17.6%) had one or more VAN levels
> 2.5 lg/ml. Of the 58 patients with one or more
detectable serum concentrations, 26 (44.8%) had
received POV therapy ≥ 10 days and 39 (67.2%)
had severe CDI (based on findings of a WBC
> 15,000 or Scr > 1.5 times the premorbid level).
Of 14 patients with other (nonsevere CDI) GI
disease, only 2 (14.3%) had GI GVHD (one each
with stage 1 and stage 2 disease); the remaining
12 patients (85.7%) had other GI pathologies
such as Crohn disease or ulcerative colitis.
VAN levels > 2.5 lg/ml were measured in 18
samples from 15 adult patients (Table 2). Of the
15 patients with levels > 2.5 lg/ml, 6 (40%)
received POV dosages of 500 mg/day, 9 (60%)
received 1000 mg/day, and 14 (93.3%) experi-
enced these levels at the time the first level was
obtained (at a median of 6 days after initiation
of POV therapy). Further, of six patients in this
group in whom multiple VAN levels were
obtained, five (83.3%) exhibited additional VAN
levels > 2.5 lg/ml. Six (40%) of the 15 had GI
disease (only one of whom had GVHD), 7
(46.6%) had been admitted to the ICU, 9 (60%)
had renal dysfunction (Clcr < 50 ml/min or
undergoing HD or CRRT), and 9 (60%) had
received a POV dosage > 500 mg/day.
Variables significantly associated with any
detectable VAN level in the bivariate analysis
(Table 3) included POV dosages > 500 mg/day
or administration ≥ 10 days, the presence of
severe CDI, and ICU admission. Variables asso-
ciated with VAN levels > 2.5 lg/ml included the
presence of GI pathology, ICU admission, and
the use of VAN retention enemas.
In the multivariate analysis (Table 4), indepen-
dent risk factors significantly associated with
detectable systemic VAN exposure included POV
dosages > 500 mg/day (OR 35.83, 95% CI 7.56–
169.8, p<0.001), the presence of severe CDI (OR
4.11, 95% CI 1.56–10.83, p=0.028), ICU admis-
sion (OR 3.80, 95% CI 1.02–14.21, p=0.032),
and the administration of POV ≥ 10 days (OR
6.71, 95% CI 1.81–24.83, p=0.0025).
Risk factors for exposure to serum VAN con-
centrations > 2.5 lg/ml included the presence of
Table 1. Serum VAN Concentrations in 117 Levels from 85 Patients with CDI, Following Administration of POV
VAN concentrations
1st 2nd 3rd 4th Total
No. of concs measured 85 21 7 4 117
No. (%) detectablea 54 (63.5%) 13 (61.9%) 5 (71.4%) 2 (40.0%) 74 (63.2%)



















Median 6 1.2 13 1.7 42.6 1.7 46 1.0 0.05–9.9
Range 5–52 0.05–9.94 3–101 0.5–3.5 8–12 0.3–3.4 6–137 0.3–1.7
CDI = Clostridium difficile infection; conc = concentration; POV = oral vancomycin; VAN = vancomycin.
aVAN levels that were detectable (≥ 0.05 lg/ml).
b“Day of therapy” refers to the number of days after the start of POV on which the vancomycin level was obtained. Levels were obtained after
at least 5 days of therapy, then every 7–10 days thereafter if POV was continued. Samples were obtained from discarded samples initially
obtained for routine clinical laboratory monitoring.











> 2.5 lg/ml (%)
≤ 500 46 60 37 (61.7) 9 (15)
501–1000 31 43 28 (65.1) 5 (11.6)
2000 8 14 11 (78.6) 5 (35.7)
Total 85 117 76 (65) 19 (16.2)
aVAN levels that were detectable (≥ 0.05 lg/ml).
bAs a percentage of the number of levels obtained in patients receiving that dosage.
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GI pathology (OR 5.17, 95% CI 1.45–18.37,
p=0.031); ICU admission (OR 3.21, 95% CI
1.00–10.28, p=0.022); the use of VAN retention
enemas (OR 4.73, 95% CI 1.10–20.39, p=0.036);
and a Clcr ≤ 50 ml/min, HD, or CRRT (OR 4.03,
95% CI 1.26–12.84, p=0.039).
Discussion
To our knowledge, this study includes the
largest set of patient data assessing systemic
VAN exposure following administration of large
dosages of POV for CDI, and it is the first to
evaluate independent risk factors for VAN expo-
sure in this population. Similar to the findings
of prior anecdotal case reports and small case
series investigating systemic absorption of
POV,7, 9, 13, 15, 17, 18, 25 we found that the pres-
ence of renal failure, conditions that alter the
integrity of GI tract, severe CDI, and the adminis-
tration of high (> 500 mg/day) or prolonged
(≥ 10 days) administration of POV are potential
risk factors for exposure to systemic VAN after
administration of POV. Unique to our study we
identified that ICU admission and the concomi-
tant use of VAN retention enemas were signifi-
cantly associated with systemic exposure to VAN.
Current SHEA/IDSA guidelines for the man-
agement of CDI suggest monitoring serum VAN
concentrations in patients with renal failure
Table 3. Bivariate Analysis of Demographic, Clinical, and Laboratory Features in 85 Patients with 117 VAN Levels Follow-
ing Administration of POV
Variable N (%)
VAN level Any VAN level > 2.5 lg/ml
Undetectable Detectablea p No (%) Yes (%) p
N 27 (31.8%) 58 (68.2%) 70 (82.4%) 15 (17.6%)
Male gender 42 (49.4) 16 (38.1) 26 (61.9) 0.22 36 (85.7) 6 (14.3) 0.42
Age ≥ 60 yrs 41 (48.2) 14 (34.1) 27 (65.9) 0.65 34 (82.9) 7 (17.1) 0.89
POV > 500 mg/dayb 40 (47.1) 2 (4.4) 43 (95.6) < 0.001 39 (86.7) 6 (13.3) 0.27
Severe CDIc 48 (56.5) 9 (18.8) 39 (81.2) 0.003 37 (77.1) 11 (22.9) 0.15
GI diseased 14 (16.5) 5 (35.7) 9 (64.3) 0.73 8 (57.1) 6 (42.9) 0.0068
ICU admission 22 (25.9) 3 (14.3) 19 (86.4) 0.037 15 (68.2) 7 (31.8) 0.043
POV ≥ 10 days 29 (34.1) 3 (10.3) 26 (89.7) 0.0019 23 (79.3) 6 (20.7) 0.59
C. difficile positive 72 (84.7) 22 (30.6) 50 (69.4) 0.57 58 (80.6) 14 (19.4) 0.31
VAN retention enema 9 (10.6) 3 (33.3) 6 (66.7) 0.91 5 (55.6) 4 (44.4) 0.026
Clcr ≤50 ml/min or HD/CRRT 28 (32.9) 7 (25) 21 (75) 0.35 19 (67.9) 9 (32.1) 0.014
CDI = Clostridium difficile infection; Clcr = creatinine clearance; conc = concentration; GI = gastrointestinal; HD/CRRT = hemodialysis/
chronic renal replacement therapy; ICU = intensive care unit; POV = oral vancomycin; VAN = vancomycin.
aVAN levels that were detectable (≥ 0.05 lg/ml).
bOf the 85 patients, 8 (9.4%) received 2000 mg/day, 29 (34.1%) received 1000 mg/day, and 42 (49.4%) received 500 mg/day. The remaining
six patients (7.1%) received daily dosages of 880, 750, 735, 375, 125, or 62 mg. Of note, only three patients received dosages < 500 mg/day.
cSevere CDI was defined as patients with white blood cell count > 15,000 or serum creatinine > 1.5 times the premorbid level.
dGI disease was defined as inflammatory bowel disease, Crohn disease, GI graft-versus-host disease, or other GI process that could have
affected the integrity of the GI tract.
Table 4. Multivariate Analysis in Patient Characteristics in 85 Patients with 117 VAN Levels Following Administration of
POV
Variable Odds ratio 95% CI p
Any detectable VAN levela
POV > 500 mg/day 35.83 7.56–169.8 < 0.001
Severe CDIb 4.11 2.76–10.83 0.028
ICU admission 3.80 1.02–14.21 0.032
POV ≥ 10 days 6.71 1.85–24.83 0.0025
VAN level > 2.5 lg/ml
GI diseasec 5.22 3.45–18.3 0.031
ICU admission 3.21 1.40–10.28 0.022
VAN retention enema 4.73 2.42–20.39 0.036
Clcr ≤ 50 ml/min or HD/CRRT 4.03 1.26–12.84 0.039
CDI = Clostridium difficile infection; Clcr = creatinine clearance; GI = gastrointestinal; conc = concentration; HD/CRRT = hemodialysis/
chronic renal replacement therapy; ICU = intensive care unit; POV = oral vancomycin; VAN = vancomycin.
aVancomycin levels that were detectable (≥ 0.05 lg/ml).
bSevere CDI was defined as patients with a white blood cell count > 15,000 or serum creatinine > 1.5 times the premorbid level.1
cGI disease was defined as inflammatory bowel disease (IBD), Crohn disease, GI graft-versus-host disease, or other process that could have
affected the integrity of the GI tract. Of 14 patients with GI disease, there were four patients with Crohn disease, four with diverticulitis/
diverticulosis, three with IBD, two with GI GVHD, and one with ulcerative colitis.
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receiving ≥ 2 g/day for prolonged durations.1
Similarly, the manufacturer’s prescribing infor-
mation for VAN capsules recommends serum
VAN monitoring for patients with renal impair-
ment or pseudomembranous colitis.26 Although
renal insufficiency (defined as an estimated
Clcr < 50 ml/min) was previously suggested as a
risk factor for systemic absorption of POV,16 we
found this to be an independent risk factor for a
VAN level > 2.5 lg/ml. A recent abstract8
reported that low concentrations of VAN, rang-
ing from 0.052 to 1.71 lg/ml, were detectable in
the plasma on days 1 or 10 of therapy in 25 of
102 patients (25%) with CDI following adminis-
tration of POV 125 mg 4 times/day for 10 days.
Patients with renal insufficiency (Scr > 1.5 mg/dl)
were more likely (79% vs 16%) to experience
detectable VAN serum concentrations
(p<0.001).8 Similarly, in our study, 21 of 28
patients (75%) with an estimated Clcr < 50 ml/
min had detectable levels, and 9 (32.1%) had
VAN levels > 2.5 lg/ml. Of five patients who
were undergoing HD or CRRT at the time a serum
concentration was obtained, all had detectable
VAN concentrations, and 60% had serum levels
> 2.5 lg/ml obtained on more than one occasion,
despite the ability of both HD and CRRT to
remove significant amounts of VAN.27, 28
Severe inflammation of the GI tract that com-
promises the integrity of the mucosal lining,
such as GVHD or severe CDI, can increase intes-
tinal permeability, resulting in increased absorp-
tion of some orally administered
drugs.5, 6, 14, 16, 17 In a recent case report, a
bone marrow transplant patient with stage IV GI
GVHD was found to have a VAN serum concen-
tration of 26.4 lg/ml after receiving POV at a
dosage of 250 mg every 6 hours for 19 days.7
Upon rechallenge with POV, the patient again
experienced detectable VAN levels with associ-
ated acute renal insufficiency. In our study, the
presence of inflammatory GI diseases such as GI
GVHD or Crohn disease was an independent
predictor of higher serum concentrations
(> 2.5 lg/ml) of VAN, and severe CDI was a
predictor of detectable VAN levels.
Previous case reports have documented signif-
icant absorption of VAN with the administration
of higher (500 mg 4 times/day) dosages of POV
in patients with CDI in the absence of renal fail-
ure, suggesting that higher dosages and/or pro-
longed administration are risk factors for the
absorption of POV.14, 16 We found both higher
(> 500 mg/day) dosages and longer (≥ 10 days)
durations of VAN therapy to be independent
risk factors for achieving detectable VAN levels.
In our study, 14 patients experienced levels
> 2.5 lg/ml at the time the first level was
obtained (at a median of 6 days after initiation
of POV therapy); of these, 6 (40%) were receiv-
ing POV dosages of only 500 mg/day and 9
(60%) were receiving 1000 mg/day. Thus clini-
cians cannot rule out the possibility of drug
exposure in patients receiving so-called lower
dosages of POV typically administered to
patients without severe CDI, if they have other
risk factors29 or if systemic absorption can be
observed early in the course of therapy.15
VAN retention enemas, administered rectally
at dosages of 500 mg 3 times/day, were adminis-
tered to 9 (10.6%) of 85 patients in our study,
and they were a significant risk factor for achiev-
ing VAN serum concentrations > 2.5 lg/ml.
Although retention enemas are typically utilized
in patients with severe disease in whom reduced
gut integrity might be expected and most often
in conjunction with high-dose POV therapy,
only 5 (55.5%) of the 9 patients receiving
enemas were receiving POV > 500 mg/day;
7 (77.7%) of 9 had severe disease.
ICU admission serves as a marker for the acu-
ity of a patient’s clinical status or condition. As
such, these patients are more likely to have renal
insufficiency or conditions that compromise the
integrity of the GI tract, such as severe CDI, that
could result in increased absorption and accu-
mulation of generally poorly bioavailable orally
administered medications.30 ICU admission was
a significant predictor of both measurable and
elevated (> 2.5 lg/ml) levels of VAN. Of note,
however, the dosage of POV was not signifi-
cantly different in ICU versus non-ICU patients
(730.7  474.2 vs 838.1  453.8 mg/day,
respectively, p=0.35).
This prospective observational single-center
case series has several limitations. Given that
patients at the University of Michigan Hospital
with confirmed or suspected CDI are adminis-
tered the 100 mg/ml oral solution POV (recon-
stituted using the IV solution) as opposed to the
VAN capsule, we could not determine if the dos-
age form might influence systemic absorption.
By excluding all patients who had been exposed
to IV VAN in the previous month, we may have
eliminated many clinically labile patients who
may have been at an increased risk for systemic
absorption of POV. In addition, given that our
analysis focused on factors found to be poten-
tially associated with systemic absorption and
exposure in previous case reports and case ser-
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ies, other unknown or unanticipated factors may
not have been identified. Lastly, it is important
to note that this study was a qualitative assess-
ment utilizing random serum samples to identify
risk factors for detectable serum concentrations
of VAN. As such, it was not a quantitative
assessment of the pharmacokinetics of POV in
high-risk patients. Because most of the serum
VAN levels were obtained using serum from dis-
carded samples initially obtained for routine
clinical laboratory monitoring, they were unli-
kely to reflect peak systemic levels of VAN.
Thus we do not know the extent or magnitude
to which individual patients may accumulate
VAN or whether higher plasma levels were
achieved but not captured in our sampling.
The resurgence in CDI and resulting increased
use of POV may place previously unidentified
patient populations at risk of systemic exposure
to VAN. We found that almost 70% of our
patients receiving POV experienced one or more
detectable serum concentrations of VAN, placing
them at risk for further accumulation that could
result in systemic toxicity including rash, red-
man syndrome, and elevated liver
enzymes.17, 25, 31–35 Because this was an obser-
vational study, we did not collect surveillance
cultures to determine the impact of low-level
vancomycin exposure on the host microbiome
or the potential for isolation or development of
resistant gram-positive organisms. Nor did we
assess adverse reactions possibly due to VAN.
However, published data suggest that VAN levels
< 10 lg/ml may be associated with the develop-
ment of resistant strains of S. aureus including
VISA and VRSA.19–21
Conclusions
Based on the results of this study, clinicians
should consider measuring VAN plasma concen-
trations early in the course of therapy in patients
who display risk factors identified in the present
study. Unique to our study, we identified that
ICU admission and the concomitant use of VAN
retention enemas were significantly associated
with systemic absorption of POV. If measurable
VAN levels are obtained, clinicians should con-
sider decreasing the dosage of POV2, 28, 29
because recent studies demonstrate that although
fecal levels of vancomycin are proportional to the
dosage of POV administered, they are much
higher than the minimum inhibitory concentra-
tion for 90% of tested strains of C. difficile, even
in patients with increased stool frequency.28
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